STOCK TITAN

Trevena Inc - TRVN STOCK NEWS

Welcome to our dedicated news page for Trevena (Ticker: TRVN), a resource for investors and traders seeking the latest updates and insights on Trevena.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Trevena's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Trevena's position in the market.

Rhea-AI Summary
Trevena, Inc. announces preliminary topline data from two Phase 1 proof-of-concept studies of TRV045, a novel sphingosine-1-phosphate receptor modulator selective for the S1P receptor subtype 1. Data shows statistically significant analgesic effect in capsaicin-induced model of neuropathic pain and evidence of CNS activity as measured by EEG power spectral analysis. Full safety and tolerability data expected in early 4Q 2023. Company to hold conference call on September 6 at 8 a.m. Eastern.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.29%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.83%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
none
-
Rhea-AI Summary
Trevena, Inc. has received a $3 million milestone payment for the Chinese approval of OLINVYK. They are also eligible to receive a $15 million non-dilutive financing tranche from R-Bridge upon the first commercial sale in China. The company expects the commercial sale to occur in 3Q 3023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.72%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
none
Rhea-AI Summary
Trevena, Inc. has received regulatory approval in China for OLINVYK, triggering a $3 million milestone payment from its partner Jiangsu Nhwa Pharmaceutical. The company expects to receive an additional $15 million upon the first commercial sale of OLINVYK in China. TRV045 topline data for two proof-of-concept studies supporting potential use in epilepsy and chronic pain is expected in 3Q 2023. The initial topline data for OLINVYK showed a statistically significant reduction in average hospital length of stay compared to patients treated with other IV opioids. Trevena also reported its financial results for Q1 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.59%
Tags
-
Rhea-AI Summary
Trevena, Inc. will release its financial results for Q1 2023 on May 15, 2023. The company will host a conference call and webcast at 8:00 a.m. ET on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-43.09%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
393.65%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.55%
Tags
conferences
Trevena Inc

Nasdaq:TRVN

TRVN Rankings

TRVN Stock Data

6.99M
18.10M
0.92%
7.95%
0.62%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Chesterbrook

About TRVN

trevena, inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target g protein coupled receptors, or gpcrs. we are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. we have identified four biased ligand drug candidates: trv130, an fda-designated breakthrough therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; trv027 was evaluated in a phase 2b study for the treatment of acute heart failure; trv734 has completed phase 1 testing for oral treatment of acute and chronic pain; and trv250 is in preclinical development for the treatment of migraine. in addition, trevena has an early stage portfolio of drug discovery programs currently in lead optimization.